Analyst Price Targets — ROIV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 26, 2026 10:46 am | Yastin Suneja | Guggenheim | $36.00 | $29.96 | TheFly | Roivant Sciences price target raised to $36 from $30 at Guggenheim |
| May 21, 2026 12:32 pm | — | Cowen & Co. | $41.00 | $32.18 | TheFly | Roivant Sciences price target raised to $41 from $38 at TD Cowen |
| May 21, 2026 10:20 am | David Risinger | Leerink Partners | $42.00 | $32.41 | StreetInsider | Roivant Sciences (ROIV) PT Raised to $42 at Leerink |
| April 16, 2026 12:57 pm | — | Piper Sandler | $40.00 | $29.26 | TheFly | Roivant Sciences assumed with an Overweight at Piper Sandler |
| March 4, 2026 11:41 am | Douglas Tsao | H.C. Wainwright | $34.00 | $28.81 | StreetInsider | Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright |
| February 10, 2026 11:05 am | — | H.C. Wainwright | $33.00 | $27.67 | TheFly | Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright |
| February 9, 2026 1:22 pm | — | Jefferies | $30.00 | $26.45 | TheFly | Roivant Sciences price target raised to $30 from $24 at Jefferies |
| February 9, 2026 11:45 am | — | Guggenheim | $30.00 | $25.82 | TheFly | Roivant Sciences price target raised to $30 from $28 at Guggenheim |
| December 18, 2025 1:30 pm | — | Guggenheim | $28.00 | $22.30 | TheFly | Roivant Sciences price target raised to $28 from $25 at Guggenheim |
| December 15, 2025 11:19 am | David Risinger | Leerink Partners | $32.00 | $22.10 | StreetInsider | Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners |
Latest News for ROIV
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ROIV.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.